Xenon Pharmaceuticals (XENE) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$913.0 million.
- Xenon Pharmaceuticals' Enterprise Value fell 3960.08% to -$913.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$913.0 million, marking a year-over-year decrease of 3960.08%. This contributed to the annual value of -$1.2 billion for FY2024, which is 9411.2% down from last year.
- Xenon Pharmaceuticals' Enterprise Value amounted to -$913.0 million in Q3 2025, which was down 3960.08% from -$977.0 million recorded in Q2 2025.
- In the past 5 years, Xenon Pharmaceuticals' Enterprise Value ranged from a high of -$249.6 million in Q3 2021 and a low of -$1.2 billion during Q4 2024
- Moreover, its 5-year median value for Enterprise Value was -$592.1 million (2022), whereas its average is -$625.2 million.
- In the last 5 years, Xenon Pharmaceuticals' Enterprise Value crashed by 21174.2% in 2021 and then soared by 3154.35% in 2023.
- Xenon Pharmaceuticals' Enterprise Value (Quarter) stood at -$551.8 million in 2021, then fell by 7.31% to -$592.1 million in 2022, then fell by 7.77% to -$638.1 million in 2023, then tumbled by 94.11% to -$1.2 billion in 2024, then rose by 26.29% to -$913.0 million in 2025.
- Its last three reported values are -$913.0 million in Q3 2025, -$977.0 million for Q2 2025, and -$549.6 million during Q1 2025.